Mammalian cell growth is governed by regulatory activities that include the products of genes such as c-myc and ras that act early in G 1 , as well as the E2F family of transcription factors that accumulate later in G 1 to regulate the expression of genes involved in DNA replication. Previous work has shown that the expression of the E2F1, E2F2, and E2F3 gene products is tightly regulated by cell growth. To further explore the mechanisms controlling accumulation of E2F activity, we have isolated genomic sequences flanking the 5 region of the E2F2 coding sequence. Various assays demonstrate promoter activity in this sequence that reproduces the normal control of E2F2 expression during a growth stimulation. Sequence comparison reveals the presence of a variety of known transcription factor binding sites, including E-box elements that are consensus Myc binding sites, as well as E2F binding sites. We demonstrate that the E-box elements, which we show can function as Mycresponsive sites, contribute in a positive fashion to promoter function. We also find that E2F-dependent negative regulation in quiescent cells plays a significant role in the cell growth-dependent control of the promoter, similar to the regulation of the E2F1 gene promoter.
The identification of regulatory activities that control cell proliferation has progressed at a rapid rate, resulting in the elucidation of a complex network of positively and negatively acting proteins that mediate the passage of cells through critical checkpoints in both G 1 and G 2 . A number of studies have shown that the growth-suppressing action of the retinoblastoma tumor suppressor protein (Rb) and other Rb family members is dependent on their ability to regulate the E2F family of transcription factors (23, 45, 46) . E2F was originally identified as a cellular transcription factor which could bind to and activate the adenovirus E2 promoter (34) but is now known to comprise a family of at least five distinct DNA binding activities, composed of the products of five distinct genes designated E2F1 to E2F5, together with heterodimeric partner proteins termed DP1 and DP2 (3, 16, 17, 21, 29, 33, 41, 50, 53, 59, 63) . E2F activity appears to play a critical role in cell growth regulation through the activation of a variety of genes that encode proteins important for DNA replication in S phase, as well as various genes that encode cell cycle regulatory proteins that facilitate the transition through the cell cycle (9, 20, 40, 44) . That E2F activity is indeed critical for cell cycle progression has been shown by the requirement for E2F function in order for Drosophila (13) and mammalian cells (28, 58) to complete the G 1 /S transition. Moreover, deregulated expression of the Drosophila E2F gene (2, 12) , or the mammalian E2F1 gene, will stimulate quiescent cells to enter S phase (32, 47, 52, 60) .
In most cases, it appears that the levels of DP proteins are not rate limiting (17, 22, 36) , whereas dramatic changes in the expression of various E2F family proteins have been observed (50, 54) . At least in part, the evolution of the E2F multigene family may reflect the varied responses of the individual family members to cell growth stimuli. For instance, whereas expression of the E2F4 gene is relatively constant through the cell cycle (16, 50) , E2F1 gene expression has been found to dramatically increase in late G 1 (33, 54) . The E2F5 gene has also been reported to be cell cycle regulated, with a peak of expression occurring in mid-G 1 , prior to the maximal activation of E2F1 (50) , although other experiments suggest that E2F5 expression may be relatively constant in fibroblast cultures (10a) .
Previous work has shown that the cell cycle control of E2F1 gene expression is largely the consequence of E2F-mediated negative control of the E2F1 promoter in quiescent cells (24, 31, 43) . This repression is likely mediated by a specific E2F-Rb family complex (E2F4-p130) that can bind to the E2F sites in the E2F1 promoter and that predominates in quiescent cells (6, 25) . Following a growth stimulation, E2F-mediated repression is relieved by the G 1 cyclin-dependent kinase-mediated phosphorylation of p130, resulting in the dissociation of p130 from E2F. Positive activation of the E2F1 promoter can then be achieved through upstream factors that likely include Sp1-and CCAAT-binding proteins.
We have now sought to further understand the mechanisms controlling E2F accumulation during a cell proliferative event by examining the control of the E2F2 gene through the isolation of DNA containing E2F2 promoter activity. Sequence analysis reveals a variety of known transcription factor binding sites including both E-box elements and E2F binding sites. Through the analysis of promoter mutants in functional assays, we demonstrate that the E-box elements can function as Mycresponsive sites and that these elements contribute in a positive fashion to promoter function. We also find that control of the promoter is effected in part by E2F-dependent negative regulation in G 0 cells via a cluster of E2F binding sites, similar to the control of the E2F1 promoter, and that E2F may play a positive role later in G 1 .
MATERIALS AND METHODS
Cell culture. Human foreskin fibroblasts (HFFs; passage 2) were obtained from Clonetics and maintained in Dulbecco modified Eagle medium (DMEM) containing 10% fetal calf serum (FCS) and were used between passage 4 and 12. REF52 cells were a gift from E. Ruley (Vanderbilt University) and were grown in DMEM containing 5% fetal calf serum (FCS)-5% calf serum and were carried for no more than 1 month after thawing. HeLa cells were obtained from the American Type Culture Collection and were maintained in Joklik modified minimum essential medium plus 5% calf serum. 293 cells were obtained from the American Type Culture Collection and were grown in DMEM containing 10% FCS. To bring cells to quiescence, cultures at 30% confluence (18 to 24 h after plating) were washed once with DMEM and then incubated in DMEM plus 0.1% FCS for 48 to 55 h. Cells were serum stimulated by addition of FCS to the media to 20%.
Northern analysis. Total RNA was isolated by the RNAzol B method (Biotec Laboratories, Inc.) Poly(A) ϩ RNA was isolated from an equal amount of total RNA from each time point with a PolyATtract mRNA isolation system (Promega) as described previously (9) . RNAs were electrophoresed in a 1.0% agarose-formaldehyde gel. The gel was washed for a total of 30 min, with three changes of water, and the RNAs were transferred to GeneScreen (NEN) as recommended by the manufacturer. Following transfer, blots were dried in a vacuum oven at 80°C for 1 h. Blots were probed with 32 P-labeled random-primed cDNAs (Prime-It II random primer labeling kit; Stratagene) and purified by using Bio-Spin chromatography columns (Bio-Rad). Blots were hybridized to 32 P-labeled probes, washed, and stripped as previously described (9) . cDNA probes include the human E2F1 cDNA, a gift from E. Harlow, human E2F2 cDNA (SacI fragment containing the coding sequence), a gift from M. IveyHoyle, and human ␤-actin cDNA acquired from Clontech.
Thymidine incorporation. HFFs were labeled with [ 3 H]thymidine (5 Ci/ml) for 60 min and then washed two times with phosphate-buffered saline and three times with cold (4°C) 10% trichloroacetic acid for a total of 1 h. Cells were then incubated with 2 ml of 0.2 N NaOH for 15 min at room temperature, and 0.5 ml was measured by scintillation counting.
Isolation of E2F2 promoter sequences. A human placenta genomic phage library (a gift from R. Lefkowitz, Duke University) was plated on 10 150-mmdiameter L plates at a density of 50,000 plaques per plate. Protocols for phage plating and the isolation of phage DNA are described in the protocol for the cDNA cloning system-gt11 (Amersham). Plaques were lifted in duplicate and screened by using a 426-bp EcoRI-to-NarI fragment containing the 5Ј-most region of the E2F2 cDNA (29) as a probe. Screening was performed as follows. Filter lifts were prewashed in 3ϫ SSC (1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-0.1% sodium dodecyl sulfate (SDS) at 42°C twice for 30 min each time. Filters were prehybridized in 50% formamide-5ϫ Denhardt's solution-5ϫ SSC-0.1% SDS-20 mM Tris (pH 7.4)-100 g of denatured salmon sperm DNA per ml at 42°C for 4 to 5 h. Filters were hybridized to the 32 P-labeled E2F2 probe in the same solution at 42°C overnight. Radioactive filters were washed in 0.5ϫ SSC-0.1% SDS starting at 50°C and going up to 65°C in 5°C increments for 20 min each, and radioactive filters were exposed to Kodak X-Omat film. Three plaques scoring positive on duplicate filters were picked, replated, and rescreened. All three of these clones remained positive during four rounds of screening.
Phage DNA was prepared from all three positive clones, digested with EcoRI, BglII, HindIII, and XbaI, and subjected to Southern analysis with the same 426-bp E2F2 probe. Two of the three clones exhibited the same restriction digest patterns. A 3.7-kb BglII-XbaI fragment from one of the two identical clones was subcloned into pBluescript II SKϪ (Stratagene), creating pE2F2-BSK. The E2F2-BSK plasmid was further digested with multiple restriction enzymes known to cut in the 5Ј untranslated region of the E2F2 cDNA. Based on the resulting restriction digest patterns, the E2F2 clone was reduced to 900 bp by removing a SmaI fragment containing positions 3Ј to ϩ161 (numbering according to cDNA [29] ), creating pE2F2-BSK(-SmaI). The 900-bp E2F2 clone was sequenced by using a Sequenase 7-deaza-dGTP sequencing kit (United States Biochemical) according to manufacturer's protocols. Transcription factor recognition sequences in the E2F2 clone were identified by using the IBI sequence analysis software MacVector (version 4.5).
RNase protection assay. RNase protection assays were performed as described previously (30) . Briefly, E2F2-BSK(-SmaI) was digested with MluI (Ϫ159), and an antisense RNA probe to E2F2 positions ϩ161 to Ϫ159 was synthesized. This probe was hybridized to various RNAs for 16 h at 42°C in a hybridization solution containing 80% formamide. RNA hybrids were digested with RNase, and the protected fragments were analyzed on a 7% polyacrylamide sequencing gel. G and A sequencing reactions were performed with an E2F2 primer corresponding to ϩ67 to ϩ84. RACE analysis. RACE (rapid amplification of cDNA ends) analysis is described in reference 27. Briefly, 293 cell poly(A) ϩ RNA was reverse transcribed by using an E2F2-specific primer corresponding to ϩ67 to ϩ84. Poly(A) tails were added to the resulting cDNAs by using terminal deoxytransferase. cDNAs were amplified by using an oligo(dT) primer and E2F2-specific primers corresponding to ϩ55 to ϩ70 (RACE2) and ϩ60 to ϩ75 (RACE1). Amplified products were subcloned into pBluescript II SKϪ (Stratagene). Fourteen clones were obtained and sequenced to determine their 5Ј ends.
Reporter plasmids and expression vectors. E2F2-luc was generated by subcloning the 900-bp E2F2 clone from E2F2-BSK(-SmaI) as a HindIII-XbaI fragment into the HindIII-NheI sites of pGL2basic (Promega). The E2F1-luc reporter plasmid, containing 242 nucleotides of E2F1 5Ј flanking sequence, has been described elsewhere (31) . E2F2-luc(-E2F) was created by oligonucleotidedirected mutagenesis using a Muta-Gene M13 in vitro mutagenesis kit (Bio-Rad) as specified by the manufacturer, with the following modifications. Escherichia coli CJ236 was directly transformed with E2F2-luc. Transformed bacteria were plated, a 50-ml culture grown to an optical density at 600 nm of 0.3, and the R408 helper phage was added at a multiplicity of infection of 10. Infected cultures were grown overnight, and E2F2-luc phage DNA was prepared according to Bio-Rad protocols, for annealing with the mutant oligonucleotides. This procedure was repeated for each successive E2F site mutation except that mutant oligonucleotides for sites 4 and 5 were annealed at the same time. The following point mutations were incorporated: (for all oligonucleotides, the wild-type sequence is followed by the mutant sequence): E2F sites 1 and 2 (Ϫ46 to Ϫ36), TTTGG CGCTAA and TTTGGAACTAA; E2F site 3 (Ϫ61 to Ϫ54), TTTCGCGG and TTTCGAAG; E2F site 4 (Ϫ80 to Ϫ73), TTTCCGCG and TTTCAACG; and E2F site 5 (Ϫ143 to Ϫ136), TTTCCGGG and TTTCAAGG.
E2F2-luc(-Ebox2) (mutant at sites 1 and 2) and E2F2-luc(-Ebox3) (mutant at sites 1, 2, and 3) reporter plasmids were created by oligonucleotide-directed mutagenesis as described above, and the following point mutations were introduced: E box site 1 (Ϫ458 to Ϫ451), CACATGTG and ATATTGAT; E box site 2 (Ϫ207 to Ϫ202), CAGGTG and ATGGAT; and E box site 3 (ϩ134 to ϩ139), CAGGTG and ATGGAT.
All mutations were verified by sequencing. A sequence change was noted in E2F2-luc(-E2F) 3Ј of the E2F site 5. Sequence from Ϫ130 to Ϫ120 reads GGG GTGGGGGGGGGTG, where the underlined nucleotides are extra sequence not found in the wild-type E2F2-luc reporter vector.
The cytomegalovirus (CMV)-E2F1 expression vector has been described elsewhere (8) . CMV-E2F2 was created in this laboratory by subcloning the BglII fragment from the full-length E2F2 clone (29) into pCDNA3 (Invitrogen). The CMV-E2F3 expression vector, encoding amino acids 132 to 425, was a gift from J. Lees (41) . CMV-Myc was a gift from S. Hann (Vanderbilt University) (19) . The control vector pRc/CMV were purchased from Invitrogen. CMV-Max and the control CMV-Neo-Bam 3 were gifts from M. Cole (Princeton University).
Gel mobility shift assays. Gel mobility shift assays to detect E2F binding activity were performed with partially purified HeLa cell extract (11) and an end-labeled plasmid DNA fragment from the dihydrofolate reductase gene (DHFR) promoter containing two E2F recognition sites as a probe, as previously described (26) . Oligonucleotides corresponding to Ϫ34 to Ϫ69 of the E2 promoter, and a mutant form of this sequence (26) , were used as control unlabeled competitors. A SmaI-MluI DNA fragment from E2F2-luc (Ϫ151 to ϩ169) and a corresponding mutant fragment from E2F2-luc(-E2F) were used as unlabeled competitors.
Transfection assays. REF52 cells were transfected by calcium phosphate coprecipitation as previously described (18) . Cells were plated the day before into 100-mm-diameter tissue culture dishes, except for the serum stimulation time courses, where 60-mm-diameter tissue culture dishes were used, and transfected at approximately 30 to 40% confluency. Cells were exposed to the CaPO 4 -DNA precipitate for 18 to 20 h. Transfected cells were then washed once with DMEM and placed into DMEM containing 0.1% FCS. For luciferase assays, transfected cells were harvested by washing the cells once in cold (4°C) phosphate-buffered saline, pelleting the cells by centrifugation at 3,000 rpm in a microcentrifuge, and resuspending the pellet in 5ϫ reporter lysis buffer (Promega) after dilution to 1ϫ. Luciferase activity was measured by using a Promega luciferase assay system kit, as specified by the manufacturer, and a Lumat LB 9501 luminometer (Berthold). ␤-Galactosidase activity was measured as described in BioTechniques (13a). All transfection assays were repeated at least three times, and representative results are shown.
RESULTS
Cell growth-dependent regulation of E2F2 expression. In view of past work demonstrating cell growth-regulated control of the E2F1 gene, and considering that differences in response to cell proliferation regulators could represent part of the overall complexity of E2F function, we have examined the expression pattern of additional members of the E2F family as a function of cell growth control. HFFs were brought to quiescence by serum starvation and then stimulated by the addition of fresh serum to promote synchronous entry to the cell cycle. Cells were harvested at quiescence or at various times following serum addition, and poly(A) ϩ RNA was analyzed by Northern blotting. As shown in Fig. 1A , expression of the E2F2 gene was cell cycle regulated with kinetics similar to that of E2F1. E2F2 mRNA levels began to increase around 12 h following serum stimulation, with peak expression occurring approximately 18 h after serum addition, a timing which represents late G 1 based on the kinetics of thymidine incorporation (Fig. 1B) . Thus, like E2F1 expression, E2F2 expression is tightly regulated in relation to cell growth. In contrast, we observed little or no fluctuation in the levels of E2F4 or E2F5 mRNAs during the cell cycle (data not shown).
Isolation of the E2F2 promoter. Given the growth-dependent regulation of the E2F2 gene, we have sought to identify the mechanisms responsible for the control of E2F2 expression through the isolation and analysis of the promoter sequences regulating E2F2 transcription. To isolate the human E2F2 promoter, we screened a human placenta genomic library by using a 426-bp fragment containing the 5Ј-most region of the E2F2 cDNA as a probe (29) . Three positive clones were isolated from a screen of approximately 500,000 recombinant phage. Two of the positive clones gave identical restriction digest patterns, and a 900-bp fragment from one, containing sequence 5Ј to position ϩ171, as determined by more detailed restriction mapping, was subcloned for further analysis. Sequence analysis of the 900-bp subclone, shown in Fig. 2A , confirmed that this DNA fragment did contain sequence from the 5Ј untranslated region of the E2F2 cDNA (underlined).
We used both RNase protection as well as a RACE procedure (27) to identify the sequence corresponding to the 5Ј end of the E2F2 mRNA. RNase protection analysis yielded four major protected fragments ranging from 140 to 168 bp (Fig.  2B ). As indicated in Fig. 2A , the largest of these protected products corresponds to a position 8 nucleotides upstream of the 5Ј end of the reported E2F2 cDNA (29) . The remaining three products correspond to sites downstream of the 5Ј end of the E2F2 cDNA and may represent additional transcription start sites, or they may result from internal RNase cleavage. Analysis of 14 clones obtained by the RACE procedure show that the 5Ј ends defined by these clones cluster around the mRNA start site mapped by the largest RNase protection product ( Fig. 2A) , arguing against the presence of additional upstream exons. We have chosen the site mapping to the largest major RNase protection product as the ϩ1 reference point.
An examination of the DNA sequence of the 900-bp clone revealed the presence of a number of putative binding sites for a variety of transcription factors (Fig. 2C) . Notably, multiple potential E2F binding elements are found in the 5Ј flanking region of the E2F2 gene. There are two overlapping E2F recognition sites close to the transcription start site and four additional potential E2F binding sites in upstream sequence. In addition, we noted binding sites for several other transcription factors known to participate in cell cycle-regulated transcription, including Myb, p53, and E-box elements that represent consensus Myc binding sites. Unlike many other E2F-regulated genes, there are no Sp1 or CCAAT recognition sequences in the E2F2 5Ј flanking sequence up to 723 bp upstream from the transcription start site.
E2F2 promoter sequences confer cell growth-regulated expression. Assays for promoter activity in the cloned 900-bp E2F2 5Ј flanking sequence, using a luciferase reporter gene, revealed an increase in luciferase activity upon transfection of increasing amounts of the E2F2-luc vector (data not shown). Given the cell cycle regulation of E2F2 gene expression, we also examined the activity of the cloned E2F2 promoter in serum-starved and -stimulated fibroblasts to test for cell cycle regulation. For comparison, we analyzed an E2F1 promoter construct under the same conditions. The E2F2-luc and E2F1-luc reporter plasmids were transfected into REF52 cells along with a ␤-galactosidase expression vector as an internal control. Transfected cells were growth arrested by serum starvation, and then serum was added to stimulate reentry into the cell cycle. Cells were harvested, and extracts were prepared every 2 to 4 h after serum addition and assayed for luciferase activity, which was normalized to ␤-galactosidase activity. As shown in Fig. 3 , E2F2 promoter activity was low in quiescent and early G 1 cells. This low level of activity was maintained as long as the cells were kept in starvation medium (data not shown). Upon serum stimulation, E2F2 promoter activity was seen to increase as cells progressed through G 1 , resulting in a 24-fold activation. A comparison with the E2F1 promoter reveals very similar patterns of activation for the two promoters. The timing of E2F2 promoter activity following serum stimulation coincides with the accumulation of the endogenous E2F2 mRNA seen by Northern analysis in the human fibroblasts ( Fig. 1) as well as REF52 cells (data not shown), occurring approximately 4 h prior to peak DNA synthesis. Thus, we conclude that the E2F2 5Ј flanking sequences do indeed possess appropriate E2F2 regulatory promoter activity.
E-box elements are important for E2F2 promoter activity. Given the cell cycle-regulated control of the E2F2 promoter, and the fact that sequence analysis revealed a variety of binding sites for cell cycle regulatory proteins (Fig. 2C) , we have sought to assess the contribution of these sites to E2F2 pro- Northern blot analysis of E2F1 and E2F2 mRNAs following stimulation of cell growth. HFFs were made quiescent by serum starvation and then serum stimulated as described in Materials and Methods. Cells were harvested at the indicated times after serum addition, and poly(A) ϩ RNA was prepared from 300 g of total RNA from each time point. Poly(A) ϩ RNA was separated by agarose gel electrophoresis and transferred to nitrocellulose. The blot was probed separately with the human E2F1, E2F2, and ␤-actin cDNAs and was exposed to Kodak X-Omat film for 9 days (for E2F1 and E2F2) or 18 h (for ␤-actin). Positions of RNA size markers are shown on the left in kilobases. The E2F1, E2F2, and ␤-actin mRNAs are indicated. (B) DNA synthesis following stimulation of cell growth. Serum-starved HFFs were serum stimulated for the indicated number of hours. Thirty minutes prior to the indicated time points, cells were incubated with [ 3 H]thymidine for 1 h. Thymidine incorporation was measured by scintillation counting as described in Materials and Methods. moter activity. Preliminary transfection assays using B-Myb and p53 expression vectors revealed that these proteins had only a modest effect on E2F2 promoter activity (data not shown). In contrast, cotransfection of a Myc expression plasmid revealed a marked, 10-fold enhancement of E2F2 promoter activity. REF52 cells were transfected with the E2F2-luc reporter vector along with various amounts of a Myc expression vector. Transfected cells were serum starved for 48 h to reduce endogenous activation of the E2F2 promoter and were then harvested for luciferase and ␤-galactosidase measurements. As shown in Fig. 4A , the E2F2 promoter was strongly activated by Myc in a dose-dependent manner, with a 10-fold increase in activity at the highest level of CMV-Myc as compared to the CMV control vector. In contrast, in the same experiment, Myc had no effect on the activity of the minimal E2F1 promoter that is cell cycle regulated (Fig. 3) (31) , which contains E2F sites but lacks E-box sequences, indicating that the Myc-induced activation of the E2F2 promoter was not simply the consequence of Myc-induced cell cycle progression.
To determine if the Myc-dependent induction of the E2F2 promoter was a direct effect of Myc binding to the E-box elements in the E2F2 promoter, we generated point mutations in the Myc recognition sequences located at Ϫ451 to Ϫ458 and Ϫ202 to Ϫ207. As shown in Fig. 4B , Myc activated the wildtype E2F2 promoter sevenfold compared to the control, whereas the mutant E2F2 promoter, lacking the two upstream E-box sites [E2F2-luc(-Ebox2)], showed a marked reduction in activation by Myc expression, only twofold compared to the control. Baseline activities in the control cells of E2F2-luc and E2F2-luc(-Ebox2) were similar.
Given the evidence that the E-box elements can allow an activation by the Myc protein, we have investigated the potential role of these elements in the normal growth-activated expression of the E2F2 promoter. REF52 cells were transfected with either E2F2-luc, E2F2-luc(-Ebox2), or E2F2-luc(-Ebox3), the latter representing a construct in which all three of the E-box elements shown in Fig. 2C were eliminated by mutation. Transfected cells were brought to quiescence by serum starvation and then stimulated by the readdition of serum. Elimina- tion of the two upstream E-box sites [E2F2-luc(-Ebox2)] reduced the serum-mediated activation of the E2F2 promoter by approximately 40% (Fig. 5A) . The additional mutation of the third potential E box element in the region downstream of transcription initiation [E2F2-luc(-Ebox3)] further reduced the level of promoter activity following serum stimulation to approximately 25% of the wild-type level.
As an alternative approach to study the role of the E-box elements in E2F2 promoter control, we have examined the effect of overexpression of the Max protein on the cell cycle activation of the wild-type E2F2 promoter. Various experiments have shown that high levels of Max, a heterodimeric Myc partner, form Max-Max homodimers that bind to E box sites but do not activate transcription (1, 37) . As shown in Fig.   5B , Max overexpression reduced the serum activation of the E2F2 promoter to 30% of the control activity, again demonstrating a role for the E-box binding sites in the cell cycleregulated expression of E2F2. We thus conclude that the E-box sites play a significant role in the cell cycle regulation of the E2F2 promoter and that Myc can activate the E2F2 promoter, dependent on these E-box elements within the promoter.
E2F-dependent control of E2F2 promoter activity. Based on the fact that E2F2 gene transcription is cell cycle regulated, together with the presence of E2F binding sites within the E2F2 promoter, we anticipated a role for E2F in the control of promoter activity. The ability of the putative E2F sites found in the E2F2 promoter to recognize HeLa E2F DNA binding activity was demonstrated by competition assays. As shown in Fig. 6A (lane 4) , an E2F2 DNA fragment containing sequence from Ϫ151 to ϩ169 relative to the transcription start site, which includes the five E2F2 promoter-proximal E2F consensus sites, effectively competed for HeLa E2F DNA binding activity at 25-fold molar excess. In contrast, a corresponding fragment in which point mutations had been incorporated into each of the potential E2F binding sites was unable to compete for the E2F DNA binding activity at the same concentration (lane 5). Further evidence that these sites are functional was provided by the ability of cotransfected E2F genes to stimulate promoter activity. Cotransfection of E2F1, E2F2, and E2F3 expression plasmids led to substantial activation of the wildtype E2F2 promoter (Fig. 6B) but not an E2F2 promoter which contains point mutations in each of the five promoter-proximal E2F binding sites that eliminate E2F binding [E2F2-luc(-E2F)] (Fig. 6C) .
To examine the role of the E2F binding sites in the cell cycle regulation of the E2F2 promoter, we used the E2F site mutant reporter vector, E2F2-Luc(-E2F). REF52 cells were transfected with either wild-type E2F2-luc or the mutant E2F2-luc (-E2F), along with CMV-␤-gal. Transfected cells were growth arrested and then stimulated to enter the cell cycle by the addition of serum. As shown in Fig. 7 , mutation of the promoter-proximal E2F binding sites resulted in a marked increase in the basal activity of the E2F2 promoter in quiescent   FIG. 3 . Cell cycle regulation of the E2F2 promoter. REF52 cells were transfected with 2.5 g of E2F2-luc or E2F1-luc and 1 g of the CMV-␤-gal vector as an internal control. Transfected cells were brought to quiescence by serum starvation for 48 h and then stimulated with serum for the indicated times. At each time point, cells were harvested, extracts were prepared, and luciferase and ␤-galactosidase activities were measured as described in Materials and Methods. Luciferase activity was normalized to ␤-galactosidase activity.
FIG. 4. Myc can activate the E2F2 promoter. (A)
The E2F2 promoter, but not the E2F1 promoter, is activated by Myc. REF52 cells were transfected with 8 g of either the E2F2-luc reporter plasmid or the E2F1-luc reporter together with the indicated amount (in micrograms) of a CMV-driven Myc expression vector along with 2 g of CMV-␤-gal. When less than 10 g of CMV-Myc was used, the control vector pRcCMV was included to bring the total amount of CMV vector added to 10 g. Transfected cells were serum starved for 48 h, at which time cells were harvested, extracts were prepared, and luciferase and ␤-galactosidase activities were measured. Luciferase activity was normalized to ␤-galactosidase activity and is plotted for each amount of cotransfected CMV-Myc as fold activation over the level of the control CMV vector, which was set at 1. (B) Activation of E2F2-luc by Myc is dependent on intact E-box elements. REF52 cells were transfected with 8 g of either wild-type E2F2-luc or an E box-site mutant, E2F2-luc(-Ebox2), in which point mutations had been incorporated into the E-box sites located at Ϫ451 to Ϫ458 and Ϫ202 to Ϫ207 along with either 10 g of CMV-Myc (ϩ) or 10 g of the control pRc/CMV (Ϫ) plus 2 g CMV-␤-gal. Transfected cells were assayed as described for panel A. fibroblasts (a 10-fold increase). This elevated activity remained relatively constant following serum stimulation, thus eliminating the normal cell cycle regulation of the promoter. We thus conclude that E2F plays a substantial role in the control of E2F2 promoter activity and that a major aspect of E2F2 gene regulation during the cell growth response results from E2F-dependent negative control of transcription in G 0 cells. The fact that the activity of the mutant promoter is consistently less than that of the fully activated wild-type promoter also suggests that the free E2F accumulating in late G 1 contributes positively to the activation of E2F2 transcription.
DISCUSSION
Considerable attention has focused on the role of regulatory activities that govern the transition of cells from a quiescent state into a cell cycle. Such studies have revealed a critical role for the cell cycle regulatory pathway that includes the G 1 cyclins and their associated kinases. The activation of these kinases leads to the phosphorylation of key regulatory proteins such as the retinoblastoma gene product, which allows the accumulation of free E2F transcription factors and the consequent activation of genes important for S phase. Other experiments have documented the role of growth factor receptorlinked signal transduction pathways that lead to the activation of transcription factors initially identified as oncogenic proteins including Fos, Jun, and Myc. The experiments we present here demonstrate that the E2F2 gene is subject to E2F-mediated negative regulation in quiescent cells, a result previously shown for the E2F1 gene. Thus, at least part of the cell cycleregulated activation of E2F2 transcription likely involves the relief of repression through the phosphorylation of Rb family proteins by G 1 cyclin-dependent kinases. Our experiments also show that E-box elements, which we show can function as Myc-responsive elements, also contribute to the activation of E2F2 transcription during G 1 , suggesting the possibility of a link between two critical G 1 regulatory pathways that govern cell proliferation.
Role of the E2F family in cell growth regulation. The E2F activity found in the cell, as defined by sequence-specific DNA binding activity, is composed of a group of heterodimeric proteins encoded by distinct but related genes. A variety of studies have now associated the E2F1 gene product with E2F-mediated positive control of cell cycle progression, including the demonstration that the E2F1 product can stimulate quiescent cells to enter S phase (32, 47, 52, 60) . The kinetics of activation of the E2F1 gene during G 1 , leading to the accumulation of E2F1 protein, closely coincides with the activation of E2F-regulated genes that encode proteins contributing substrates to DNA replication such as DHFR, as well as genes encoding proteins that directly participate in DNA replication such as DNA polymerase ␣ and proliferating cell nuclear antigen (44, 62) . Indeed, recent experiments have shown a link between the ability of E2F1 to induce S phase and the activation of many of these DNA synthesis genes (9) .
Likewise, it appears that the E2F2 and E2F3 products may also play a role in promoting cell cycle progression through the activation of key target genes at G 1 /S (10) . Other experiments have shown that E2F2 has oncogenic capacity (61). These observations, together with experiments which demonstrate that the transcription of the E2F2 gene is tightly regulated during a proliferative response leading to an accumulation of E2F2 activity that coincides with entry to S phase (25) , all suggest that E2F1, E2F2, and E2F3 may play similar roles in promoting the G 1 /S transition.
In contrast, other E2F proteins may function primarily to negatively regulate cell growth in conjunction with Rb family member proteins. Various experiments have shown that a complex of E2F with Rb and Rb-related proteins has the capacity to actively repress transcription directed by otherwise functional promoters (5, 51, 56, 57) . Under normal in vivo conditions, E2F-mediated repression may largely represent the activity of the E2F4 or E2F5 protein in association with the Rb-related p130 protein since these E2F-p130 complexes predominate in quiescent cells, coincident with the E2F-dependent repression of genes such as E2F1 (24, 31, 43) , B-myb (38) , and E2F2 as we show here.
Control of E2F2 gene expression. The experiments that we present here demonstrate that the cell cycle-regulated expression of the E2F2 gene involves an E2F-mediated negative control of transcription in quiescent cells. As discussed above, this repression is likely mediated by an E2F4-or E2F5-p130 complex. As the E2F4/5-p130 complex disappears following stimulation of cell growth (7, 25) , as a consequence of the FIG. 5 . E-box elements are required for full activity of the E2F2 promoter. (A) Effects of mutation of E-box elements. REF52 cells were transfected with 2.5 g of the wild-type E2F2-luc plasmid (squares) or E2F2-luc plasmids in which either two (triangles) or all three (circles) E-box elements were mutated, together with 2.5 g of control CMV-Neo-Bam 3 as carrier and 1 g of CMV-␤-gal. Cells were brought to quiescence by serum starvation for 48 h and then serum stimulated. Transfected cells were harvested at the indicated time points following the addition of serum, extracts were prepared, and luciferase and ␤-galactosidase activities were measured. Luciferase activity was normalized to ␤-galactosidase activity and is plotted versus hours of serum stimulation for each reporter plasmid. (B) Effect of Max coexpression. REF52 cells were transfected with 2.5 g of the wild-type E2F2-luc plasmid together with either 3.5 g of a Max expression vector (open squares) or 3.5 g of control CMV-NeoBam 3 vector (filled squares) and 1 g of CMV-␤-gal. Transfected cells were treated as described for panel A.
action of G 1 cyclin-dependent kinases (55), the repression is abolished and the promoter can then become active. In the case of E2F1, positive transcriptional activity may largely depend on the presence of Sp1 and CCAAT binding sites (4, 24, 31, 43) . In contrast, the E2F2 promoter does not contain these binding sites, and the results we present here indicate that the activation of E2F2 transcription, following relief of repression, appears to depend at least in part on the series of E-box elements found in the promoter. It is also true that other promoter elements must contribute to the full transcriptional activity of the promoter since the mutation of the E-box elements did not completely eliminate activity (approximately 30% remaining activity compared to the wild-type level). These other factors could include positively acting E2F proteins that accumulate in late G 1 such as E2F1, E2F2, and E2F3 since the E2F site mutant promoter was also only 30% as active as the wild-type promoter following serum stimulation. Moreover, a double mutant in which all of the E2F and E-box sites were eliminated resulted in a promoter with very low activity that was not growth regulated (data not shown).
Several lines of evidence suggest a connection between the action of Myc and the E2F pathway. First, both E2F and Myc are able to stimulate quiescent cells to enter S phase, a process which is then accompanied by an induction of apoptosis (14, 35, 42, 47, 52, 60) . Second, a variety of studies have suggested a similarity between the action of adenovirus E1A, which activates E2F, and Myc, particularly with respect to the oncogenic activity of the two proteins (39, 48, 49) . The fact that Myc can bind to the E-box elements in the E2F2 promoter (data not shown), and can activate the E2F2 promoter dependent on the E box elements, suggests the possibility of a direct role for Myc in the activation of the E2F2 gene. Moreover, our additional experiments show that overexpression of Myc by using a recombinant adenovirus can lead to activation of E2F2 gene expression (data not shown). However, we cannot rule out a role for other E-box binding activities in promoting E2F2 transcription, and it is also true that the ability of Myc to activate E2F2 expression could be an indirect effect. For instance, Myc could achieve an activation of the E2F2 gene via the induction of the cdc25A phosphatase, which has been suggested to be a direct target for Myc in recent experiments (15) . The activation of cdc25A expression, which would lead to an activation of G 1 cyclin-dependent kinase activity, could then result in activation of the E2F2 gene due to the inactivation of the E2F-p130 repressor. Certainly, further studies are required to establish a direct connection between Myc and the accumulation of E2F, FIG. 7 . E2F-dependent control of the E2F2 promoter. REF52 cells were transfected with 2.5 g of either the reporter plasmid E2F2-luc or an E2F-site mutant vector, E2F2-luc(-E2F), plus 2.5 g of an empty CMV vector, CMVNeo-Bam 3 , as carrier DNA and 1 g of CMV-␤-gal. Cells were brought to quiescence by serum starvation for 48 h and then serum stimulated. Cells were harvested at the indicated time points following the addition of serum, extracts were prepared, and luciferase and ␤-galactosidase activities were measured. Luciferase activity was normalized to ␤-galactosidase activity.
FIG. 6. E2F-dependent control of E2F2 promoter activity. (A) E2F binds to the E2F2 promoter. Gel mobility shift assays were performed with partially purified HeLa cell extract and an end-labeled plasmid DNA fragment from the DHFR promoter containing two overlapping E2F recognition sites as a probe (lane 1). Competition assays were performed by adding 25-fold molar excess of unlabeled oligonucleotides or fragments to the gel shift reactions. Competitors include E2F recognition site oligonucleotide from the E2 promoter (Ϫ34 to Ϫ69) (lane 2), a mutant form of this sequence (lane 3), a SmaI-MluI DNA fragment containing E2F sites from E2F2-luc (Ϫ151 to ϩ169) (lane 4), and a mutant form of this sequence (lane 5). E2F-DNA complexes in lanes 1, 3, and 5 are indicated and reflect primarily the binding of free E2F4 and E2F5 that predominate in HeLa extracts. (B) E2F family members activate the E2F2 promoter. REF52 cells were transfected with 8 g of the E2F2-luc reporter vector and 5 g of CMV-driven expression vectors for either E2F1, E2F2, E2F3, or a control CMV vector, pCDNA3, as indicated, along with 2 g of CMV-␤-gal as an internal control. Transfected cells were serum starved for 48 h, at which time cells were harvested, extracts were prepared, and luciferase and ␤-galactosidase activities were measured. Luciferase activity was normalized to ␤-galactosidase activity and is plotted for each cotransfected CMV expression vector as fold activation over the control pCDNA3 level, which was set at 1. (C) E2F sites are required for E2F-mediated activation of the E2F2 promoter. REF52 cells were transfected with 8 g of either wild-type E2F2-luc or the mutant E2F2-luc(-E2F) and 5 g of either CMV-E2F1 or the control pcDNA3 as indicated along with 2 g of CMV-␤-gal. Transfected cells were treated as described for panel B.
but the results presented here suggest the possibility of a direct connection between these two critical cell growth regulatory pathways.
